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Major depressive disorder (MDD) is a highly prevalent disorder, which has been associated with an abnormal
response of the hypothalamus–pituitary–adrenal (HPA) axis. Reports have argued that an abnormal HPA axis
response can be due to an altered P-Glycoprotein (P-GP) function. This argument suggests that genetic poly-
morphisms in ABCB1 may have an effect on the HPA axis activity; however, it is still not clear if this influences
the risk of MDD. Our study aims to evaluate the effect of ABCB1 C1236T, G2677TA and C3435T genetic
polymorphisms on MDD risk in a subset of Portuguese patients. DNA samples from 80 MDD patients and 160
control subjects were genotyped using TaqMan SNP Genotyping assays. A significant protection for MDD
males carrying the T allele was observed (C1236T: odds ratio (OR) = 0.360, 95% confidence interval [CI]: [0.140–
0.950], p = 0.022; C3435T: OR = 0.306, 95% CI: [0.096–0.980], p = 0.042; and G2677TA: OR = 0.300, 95% CI: [0.100–
0.870], p = 0.013). Male Portuguese individuals carrying the 1236T/2677T/3435T haplotype had nearly 70% less
risk of developing MDD (OR = 0.313, 95% CI: [0.118–0.832], p = 0.016, FDR p = 0.032). No significant differences
were observed regarding the overall subjects. Our results suggest that genetic variability of the ABCB1 is
associated with MDD development in male Portuguese patients. To the best of our knowledge, this is the first
report in Caucasian samples to analyze the effect of these ABCB1 genetic polymorphisms on MDD risk.
Introduction
Major depressive disorder (MDD) is a highly preva-lent disorder, with a lifetime risk of 10–25% in women
and 5–12% in males (Compton et al., 2006). Depression has
been associated with an abnormal response of the hypothal-
amus–pituitary–adrenal (HPA) axis and some authors sug-
gest that the normalization of HPA axis hyperactivity is a
crucial step in remission (Holsboer, 2000; Binder et al., 2009).
Glucocorticoid hormones, secreted by the adrenal cortex, are
potent modulators of neuronal activity and are involved in
the maintenance of the basal activity of the HPA axis (Binder
et al., 2009). The physiological access of endogenous gluco-
corticoids to the brain is important for HPA homeostasis.
Studies in animal models have proved that the absence of P-
Glycoprotein (P-GP) function at the blood–brain barrier
(BBB), leads to deep changes in the activity and regulation of
the HPA system, suggesting that P-GP may regulate the HPA
axis activity (Muller et al., 2003).
P-GP is an ATP-driven efflux pump involved in the phar-
macokinetics of P-GP substrate drugs and in the efflux of toxic
substances and metabolites, such as glucocorticoids (Kimchi-
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Sarfaty et al., 2007b). This transporter molecule is encoded by
the ABCB1 gene (also called MDR1), and is expressed on the
epithelial cells of the intestine, canalicular membrane of hepa-
tocytes, and on the endothelial cells of the BBB (Ambudkar
et al., 1999).
The overallABCB1 activity depends on two parameters: the
level of expression of the ABCB1 gene, which controls the
amount of protein that is synthesized, and the functionality of
the P-GP that determines transporter effectiveness and sub-
strate recognition (Hoffmeyer et al., 2000). Several single-
nucleotide polymorphisms (SNPs) have been studied in the
ABCB1 gene. Among these, polymorphisms in exon 12
(C1236T; rs1128503), in exon 21 (G2677TA; rs2032582), and
exon 26 (C3435T; rs1045642) are the ones most reported
(Hoffmeyer et al., 2000; Leschziner et al., 2007). Studies re-
garding the effect of these ABCB1 polymorphisms on P-GP
expression and function are not consensual (Borst and Elfer-
ink, 2002). Regarding ABCB1 C1236T synonymous polymor-
phism, some reports found altered drug responses associated
with 1236CC (Schaich et al., 2009) and 1236TT variants (Zhang
et al., 2008), while others were unable to find any relationship
(Estrela Rde et al., 2009). Reports regarding the influence of
synonymous C3435T polymorphism are inconclusive (Hod-
ges et al., 2011), and the exact influence of this polymorphism
is not known. Several lines of evidence have indicated that
this polymorphism affects the expression (Hoffmeyer et al.,
2000) and function (Compton et al., 2006) of P-GP, whereas
others reported an altered P-GP conformation despite the fact
that levels of mRNA and protein were similar (Kimchi-Sarfaty
et al., 2007b). Tri-allelic G2677TA nonsynonymous polymor-
phism has been also widely reported, since its variants are
known to induce amino acid modification (Ala893 to Ser/
Thr893) (Leschziner et al., 2007). This polymorphism is also
known to affect P-GP functionality (Hodges et al., 2011).
Despite functional studies, investigations focusing on the
influence of P-GP polymorphisms and the risk of depression
are scarce and have only been conducted in Asian (Qian et al.,
2006; Fujii et al., 2012) and Mexican American patients (Dong
et al., 2009). This article examines whether common genetic
polymorphisms in the ABCB1 gene, previously reported to be
associated with antidepressant responses, might be a predic-
tor of risk for MDD in a subset of Portuguese patients.
Materials and Methods
Patients
From a total of 92 Portuguese MDD patients followed in a
18-month follow-up study at Magalha˜es Lemos Hospital, 80
patients agreed to participate in the genetic study (21 males
and 59 females), aged 18–60, with a median age of 41.5 years
(mean age 40.48; standard deviation 11.06). Participants in the
clinical sample were recruited in the outpatient clinic at the
Magalha˜es Lemos Hospital and as part of a broader research
on the social-cognitive predictors of pharmacological re-
sponses to depression (Carvalho, 2012). Patients with the
suspicion of depression were sent to the clinic by their family
doctor and those whose clinical interview confirmed the di-
agnosis of depression were submitted to further evaluation
for major depression using the Structured Clinical Interview
for DSM Axis I Disorders (SCID-I), and for personality dis-
orders using the Axis II Disorders (SCID-II). Subjects with
more than one previous depressive episode, chronic depres-
sion, severe physical illness, psychiatric disorders with psy-
chotic symptoms, substance dependence, or personality
disorders were excluded from the study. Age- and gender-
matched healthy control individuals were recruited from the
same city. These healthy controls consisted of 160 individuals
(42 males and 118 females) with median age of 41 years (mean
age 40.48; standard deviation 11.08), collected among the
blood donors of the Portuguese Institute of Oncology–Porto.
The blood donors completed a health questionnaire, and were
interviewed by a physician about their medications and
possible chronic illnesses. The study was approved by the
ethics committee of Magalha˜es Lemos Hospital. Written in-
formed consent according to The Code of Ethics of the World
Medical Association (Declaration of Helsinki) was obtained
from each individual after explanation of the study.
Sample collection and DNA extraction
Peripheral blood samples were collected following the stan-
dard venipuncture technique in EDTA-containing tubes, and
the genomic DNA was extracted from the whole blood with a
commercial kit (E.Z.N.A.–Omega Bio-tek, Norcross, USA), ac-
cording to the manufacturer’s instructions and stored at - 20C.
C1236T, G2677TA, C3435T ABCB1 polymorphism
analysis
The C1236T, G2677TA, C3435T ABCB1 polymorphism
analysis was carried using TaqMan SNP Genotyping Assays
C___7586662_10; C_11711720C_30 and C_11711720D_40;
C___7586657_20, respectively (Applied Biosystems, Foster
City, CA). Reactions were performed on an Applied Biosys-
tems 7300 Real Time PCR System (Applied Biosystems) with a
5mL final volume mixture containing 1·TaqMan Genotyping
Master Mix (Applied Biosystems), 900 nM of each primer,
200 nM of probes labeled with either FAM or VIC, and 10 ng
of extracted DNA. Thermal cycling conditions were 10 min at
95C followed by 45 cycles (or 50 cycles forG2677TA) of 15 s at
95C and 1 min at 60C. Allelic discrimination was performed
by measuring endpoint fluorescence using an ABI PRISM
7300 Sequence Detection System (Applied Biosystems). Gen-
otyping data were read blind to the clinical course of illness
and, in case of ambiguous genotypic data, experiments were
repeated for determining the genotype of every individual.
Statistical analysis
Data preparation and analysis were carried out using the
computer software PAWS Statistics 18 (release 18.0.0) and Epi
Info (version 6.04a). A 5% level of significance was used in the
chi-square (v2) analysis to compare the categorical variables.
The odds ratio (OR) and 95% confidence interval (CI) were
calculated as a measure of association between genotypes and
MDD risk. The Fisher’s exact test was used for tables con-
taining cells, where values are less than five individuals. The
Hardy–Weinberg equilibrium was tested by a v2 test to
compare the observed versus the expected genotype fre-
quencies. Measures of linkage disequilibrium (LD), re-
presented as D¢ and r 2, were calculated from the haplotype
frequency using the expectation-maximization (EM) algo-
rithm with SNP & Variation Suite 7 free trial (Golden Helix)
software. In addition, to correct for multiple comparison
testing, adjusted p-values were determined using the false
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discovery rate (FDR) method. A posteriori power analysis
was performed using Quanto software (version 1.0; http://
hydra.usc.edu/gxe) with input of the following variables:
case–control study design, significance level (a)< 0.05 (two
sided), model of inheritance = log additive, minor allele fre-
quency = 0.406, and genetic effect for OR (‡ 1.75 and
£ 0.55). This study achieved a statistical power of 80% for the
minor allele of ABCB1 C1236T, which exhibited the lowest
allele frequency among the three polymorphisms.
Results
Allele and genotype frequencies of ABCB1 gene
The genotype and allele frequencies of the ABCB1 C1236T,
C3435T and C2677TA polymorphisms are shown in Table 1.
No significant deviations from the Hardy–Weinberg equilib-
rium proportions were observed both in controls and cases
(Table 1). LD pairwise analysis revealed a strong LD between
C1236T and G2677TA (D¢ = 0.88, r2 = 0.75) and C3435T and
G2677TA (D¢ 0.83, p = 0.59), while C1236T and C3435T loci
were in moderate LD (D¢ = 0.67, r2 = 0.40).
Allele and genotype association with MDD risk
To estimate the influence of ABCB1 polymorphisms in the
development of MDD, allele and genotype frequencies were
compared between MDD patients and controls. Our results did
not reveal any statistically significant association (Table 1).
However, a tendency of a lower MDD risk was verified for
1236TT genotype carriers (OR= 0.699; 95% CI: [0.309–1.582];
p= 0.390). Similar results were found for individuals carrying
the 2677TT variant (OR= 0.615; 95% CI: [0.248–1.525]; p= 0.291).
Nevertheless, when data were stratified according to gen-
der, a significant association was verified among male pa-
tients (Table 2). Carriers of the variant T allele in C1236T,
C3435T, and G2677TA polymorphisms had lower risk of de-
veloping MDD (OR = 0.360, 95% CI: [0.140–0.950], p= 0.022;
OR = 0.306, 95% CI: [0.096–0.980], p= 0.042; OR= 0.300, 95%
CI: [0.100–0.870], p= 0.013, respectively).
Haplotype association with MDD risk
To estimate the combined influence of ABCB1 polymor-
phisms in the risk of MDD development, haplotype analysis
was carried out. A total of seven different haplotypes were
identified using the SVS software (Table 3). Although haplo-
type analysis did not reveal any significant association with
MDD diagnosis regarding the overall subjects, TTT haplotype
was associated to a lower risk of MDD development in male
subjects (OR = 0.313, 95% CI: [0.118–0.832], p= 0.016). The as-
sociation remained statistically significant after multiple
comparisons adjustment (FDR p = 0.032).
Comparison of ABCB1 genotype frequencies
with reports from the literature
To verify if our control subjects are similar to other Cauca-
sian populations, we compared the frequencies of the genetic
polymorphisms evaluated in this study with the observed
frequencies in the control samples from other reports. Geno-
type and allele frequencies of our controls were not different
from what is reported in the literature, regarding the Portu-
guese population (C1236T: v2 = 4.81, DF= 2, p= 0.09;G2677TA:
v2= 4.84, DF= 2, p = 0.089; C3435T: v2 = 4.79; DF = 2; p= 0.091).
Table 1. Allele and Genotype Frequencies of ABCB1 Polymorphisms and Risk for Major Depressive Disorder
SNP Alleles/genotypes
Controls Cases HWE p
OR 95% CI p-ValueN % N % Controls Cases
C1236T C 190 59.4 101 63.0 0.395 0.953 Referent
T 130 40.6 59 37.0 0.850 [0.570–1.290] 0.428
CC 59 36.9 32 40.0 Referent
CT 72 45.0 37 46.2 0.947 [0.528–1.701] 0.857
TT 29 18.1 11 13.8 0.699 [0.309–1.582] 0.390
T Carrier 101 63.1 48 60.0 0.638 [0.505–1.520] 0.638
C3435T C 185 57.8 91 56.9 0.413 0.956 Referent
T 135 42.2 69 43.1 1.040 [0.700–1.550] 0.845
CC 56 35.0 26 32.5 Referent
CT 73 45.6 39 48.8 1.151 [0.628–2.110] 0.650
TT 31 19.4 15 18.8 1.042 [0.481–2.256] 0.916
T Carrier 104 65.0 54 67.5 1.118 [0.633–1.977] 0.700
G2677TA G 195 60.9 101 63.1 0.891 0.953 Referent
T 120 37.5 55 34.4 0.880 [0.580–1.350] 0.548
A 5 1.6 4 2.5 1.540 [0.340–6.800] 0.500*
GG 59 36.9 32 40.0 Referent
GT 72 45.0 36 45.0 0.922 [0.512–1.659] 0.786
GA 5 3.1 1 1.2 0.369 [0.041–3.294] 0.661*
TT 24 15.0 8 10.0 0.615 [0.248–1.525] 0.291
AA ND - ND - ** ** **
TA ND - 3 3.8 ** ** 0.049*
Variant Carrier 101 63.1 48 60.0 0.876 [0.505–1.520] 0.638
Bold values indicate p< 0.05.
*One cell count is less than 5, Fisher’s exact test was used.
**One cell count is 0, unable to calculate OR.
OR, odds ratio; ND, not detected; HWE, Hardy–Weinberg equilibrium; CI, confidence interval; SNP, single-nucleotide polymorphisms.
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Genotype frequency distribution of the C1236T SNP in our
study group was not significantly different than other Cau-
casian populations, such as Czech, French, German, and
Hungarian. However, significant differences were found with
other ethnic groups, such as Chinese, Indian, Japanese,
Turkish, and Malay populations (Table 4). Similar results
were found for G2677TA (Table 4). Concerning C3435T
polymorphism, no significant differences were found be-
tween our study and the Mediterranean populations. How-
ever, significant differences were found for other Caucasian
populations such as British, German, Hungarian, Czech, and
Polish (Table 4).
Discussion
We investigated three common SNPs in the ABCB1 gene
(C1236T, G2677TA and C3435T) in a subset of Portuguese
patients with MDD. To the best of our knowledge, no reports
have been published in Caucasian populations regarding the
effect of these ABCB1 genetic polymorphisms on MDD risk.
Table 2. Allele and Genotype Frequencies of ABCB1 Polymorphisms and Risk
for Major Depressive Disorder in Males
SNP Alleles/genotypes
Controls Cases HWE p
OR 95% CI p-ValueN % N % Controls Cases
C1236T C 51 60.7 34 81.0 0.755 0.736 Referent
T 33 39.3 8 19.0 0.360 [0.140–0.950] 0.022
CC 15 35.7 14 66.7 Referent
CT 21 50.0 6 28.6 0.306 [0.096–0.980] 0.042
TT 6 14.3 1 4.8 0.179 [0.019–1.675] 0.200*
T Carrier 27 64.3 7 33.3 0.278 [0.092–0.839] 0.020
C3435T C 48 57.1 33 78.6 0.418 0.211 Referent
T 36 42.9 9 21.4 0.36 [0.140–0.920] 0.018
CC 15 35.7 12 57.1 Referent
CT 18 42.9 9 42.9 0.625 [0.207–1.883] 0.402
TT 9 21.4 ND - ** ** 0.016*
T Carrier 27 64.3 9 42.9 0.417 [0.143–1.215] 0.105
G2677TA G 53 63.1 35 81.0 0.633 0.359 Referent
T 30 35.7 6 14.3 0.300 [0.100–0.870] 0.013
A 1 1.2 1 2.4 1.510 [0.000–57.66] 1.000*
GG 16 38.1 14 66.7 Referent
GT 20 47.6 6 28.6 0.343 [0.107–1.094] 0.066
GA 1 2.4 1 4.8 1.143 [0.065–20.018] 1.000*
TT 5 11.9 ND - ** ** 0.069*
AA ND - ND - ** ** **
TA ND - ND - ** ** **
Variant Carrier 20 47.6 6 28.6 0.308 [0.102–0.925] 0.032
Bold values indicate p < 0.05.
*One cell count is less than 5, Fisher’s exact test was used.
**One cell count is 0, unable to calculate OR.
Table 3. Haplotype Frequencies Derived from ABCB1 C1236T, G2677TA and C3435T Polymorphisms
in Control Subjects and in Patients with Major Depressive Disorder
Haplotype Controls frequency Cases frequency OR 95% CI p-Value FDR p-Value
CGC vs. Non CGC
Overall 0.481 0.514 1.153 [0.786–1.691] 0.468 0.818
Males 0.511 0.735 2.769 [1.205–6.363] 0.015 0.058
TTT vs Non TTT
Overall 0.316 0.327 1.060 [0.705–1.593] 0.778 0.908
Males 0.345 0.142 0.313 [0.118–0.832] 0.016 0.032
CGT vs. Non CGT
Overall 0.072 0.082 1.160 [0.573–2.349] 0.679 0.950
Males 0.071 0.051 0.692 [0.138–3.468] 0.653 0.870
TGC vs. Non TGC
Overall 0.049 0.031 0.627 [0.225–1.749] 0.368 0.860
Males 0.048 0.048 1.000 [0.175–5.699] 1.000 1.000
TTC vs. Non TTC 0.034 0.007 0.196 [0.027–1.398] 0.071 0.497
CTT vs. Non CTT 0.022 0.006 0.282 [0.034–2.314] 0.209 0.731
CAC vs. Non CAC 0.011 0.013 1.241 [0.219–7.021] 0.807 0.807
Bold values indicate p < 0.05.
FDR, false discovery rate.
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Furthermore, the previous reports associating the risk of
MDD and functional polymorphisms in ABCB1 were con-
ducted in Asian populations, and have only evaluated the
effect of C1236T and C3435T polymorphisms in haplotype
analysis. We included in the study, a third polymorphism in
the ABCB1 haplotype analysis, the triallelic G2677TA func-
tional genetic polymorphism.
We demonstrated a significant protection for MDD only in
males carrying the T allele in the evaluated polymorphisms.
Moreover, the haplotype analysis revealed that male indi-
viduals carrying the TTT haplotype have nearly 70% less risk
of developing MDD. Overall, the case–control analysis
showed no association between the risk of MDD and the
presence of a specific allele, genotype, or haplotype. Our re-
sults seem to indicate that the influence of ABCB1 functional
polymorphism in the risk of MDD is gender specific.
Although several reports addressed the influence of these
ABCB1 genetic polymorphisms in antidepressant responses,
only two studies have evaluated the association of these
common polymorphisms in the ABCB1 gene and the risk of
depression (Qian et al., 2006; Fujii et al., 2012). Fujii et al. (2012)
observed, in a large group of Japanese subjects that, carriers of
the 3435T allele or 1236T-3435T haplotype were more com-
mon in patients than in controls, suggesting that C3435T may
Table 4. Allele and Genotype Frequencies for the ABCB1 C1236T, G2677TA, and C3435T SNPs
in Portuguese Subjects and in Other European and Asian Populations
Population N T% CC% (N) CT% (N) TT% (N) p-Value Ref.
C1236T Portuguese 160 40.6 36.9 (59) 45.0 (72) 18.1 (29) - This study
Portuguese 100 46.0 25.0 (25) 58.0 (58) 17.0 (17) 0.090 (Correia et al., 2009)
French 223 42.0 33.0 (74) 49.0 (110) 17.5 (39) 0.686 ( Jeannesson et al., 2007)
German 461 41.0 34.3 (158) 49.2 (227) 16.5 (76) 0.650 (Cascorbi et al., 2001)
Hungarian 503 44.3 33.2 (167) 44.9 (226) 21.9 (110) 0.524 (Sipeky et al., 2011)
Czech 189 44.5 31.7 (60) 47.1 (89) 21.2 (40) 0.561 (Pechandova et al., 2006)
Polish 139 41.4 35.3 (49) 46.8 (65) 18.0 (25) 0.949 (Tan et al., 2004)
Chinese 206 63.8 15.5 (32) 41.3 (85) 43.2 (89) <0.001 (Tan et al., 2005)
Indian 87 67.2 13.8 (12) 37.9 (33) 48.3 (42) <0.001 (Chowbay et al., 2003)
Japanese 1100 60.0 16.3 (179) 46.7 (514) 37.0 (407) <0.001 (Fujii et al., 2012)
Malay 92 62.5 12.0 (11) 44.6 (41) 43.5 (40) <0.001 (Chowbay et al., 2003)
Korean 232 61.9 11.6 (27) 53.0 (123) 35.4 (82) <0.001 (Lee et al., 2005)
Turkish 100 54.5 20.0 (20) 51.0 (51) 29.0 (29) 0.009 (Gumus-Akay et al., 2008)
Population N T% CC% (N) CT% (N) TT% (N) p-Value Ref.
C3435T Portuguese 160 42.2 35.0 (56) 45.6 (73) 19.4 (31) - This study
Portuguese 100 57.0 22.8 (23) 57.9 (58) 19.3 (19) 0.091 (Correia et al., 2009)
Spanish 408 48.0 26.0 (106) 52.0 (212) 22.0 (90) 0.101 (Bernal et al., 2003)
French 222 46.0 28.0 (61) 52.0 (116) 20.0 (45) 0.275 ( Jeannesson et al., 2007)
Italian 450 47.8 25.6 (115) 53.3 (240) 21.1 (95) 0.071 (Palmieri et al., 2005)
British 280 53.9 21.8 (61) 48.6 (136) 29.6 (83) 0.004 (Onnie et al., 2006)
German 461 53.9 20.8 (96) 50.5 (233) 28.6 (132) <0.001 (Cascorbi et al., 2001)
Hungarian 503 52.7 22.3 (112) 50.1 (252) 27.6 (139) 0.003 (Sipeky et al., 2011)
Czech 189 56.5 21.2 (40) 44.9 (85) 33.9 (64) <0.001 (Pechandova et al., 2006)
Polish 173 52.2 21.6 (30) 52.5 (73) 25.9 (36) 0.021 (Tan et al., 2004)
Chinese 206 34.7 42.2 (87) 46.1 (95) 11.7 (24) 0.091 (Tan et al., 2005)
Indian 87 62.3 18.4 (16) 36.8 (32) 44.8 (39) <0.001 (Chowbay et al., 2003)
Japanese 1100 40.0 35.0 (386) 50.0 (552) 15.0 (162) 0.279 (Fujii et al., 2012)
Population N A% T% GG% (N)
GT+
GA% (N)
TT+TA+
AA% (N) p-Value Ref.
G2677TA Portuguese 160 1.6 37.5 36.9 (59) 48.1 (77) 15.0 (24) - This study
Portuguese 100 NE 47.5 31.0 (31) 43.0 (43) 26.0 (26) 0.089 (Cavaco et al., 2003)
French 225 45.0 28.4 (64) 52.4 (118) 19.1 (43) 0.189 ( Jeannesson et al., 2007)
Italian 450 2.0 43.6 28.0 (126) 55.1 (248) 16.9 (76) 0.111 (Palmieri et al., 2005)
British 285 2.5 39.6 33.0 (94) 49.8 (142) 17.2 (49) 0.601 (Onnie et al., 2006)
German 461 1.9 41.6 31.0 (143) 51.2 (236) 17.8 (82) 0.365 (Cascorbi et al., 2001)
Hungarian 503 1.1 44.1 30.6 (154) 48.3 (243) 21.1 (106) 0.152 (Sipeky et al., 2011)
Czech 189 0.5 46.0 29.6 (56) 48.1 (91) 22.2 (42) 0.152 (Pechandova et al., 2006)
Polish 139 1.1 41.4 33.8 (47) 47.5 (66) 18.7 (26) 0.668 (Tan et al., 2004)
Chinese 206 11.4 36.4 27.7 (57) 49.0 (101) 23.3 (48) 0.062 (Tan et al., 2005)
Indian 87 6.9 59.8 13.8 (12) 39.1 (34) 47.1 (41) <0.001 (Chowbay et al., 2003)
Japanese 1100 18.0 39.0 17.5 (193) 50.9 (560) 31.5 (347) <0.001 (Fujii et al., 2012)
Korean 632 17.1 39.1 19.1 (121) 49.4 (312) 31.5 (199) <0.001 (Lee et al., 2005)
Turkish 70 ND 47.0 30.0 (21) 44.3 (31) 25.7 (18) 0.144 (Sapmaz et al., 2008)
Bold values indicate p< 0.05.
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have a role in MDD development risk. However, regarding
the triallelic SNP, G2677TA, the authors did not find any sig-
nificant differences in allelic and genotypic frequencies be-
tween cases and controls. In another study, Qian et al. (2006)
evaluated the effect ofC3435T andG2677TApolymorphisms in
mood disorders, including depression. No significant associa-
tion between this C3435T polymorphism and the risk of de-
veloping mood disorder was found, but a higher frequency of
2677A was observed in patients with mood disorders than in
controls ( p< 0.05) (Qian et al., 2006). The putative reasons for
these discrepancies are widely discussed in the article by Fujii
et al. (2012), and are related to the sample size and the hetero-
geneity of the patients used in the Qian et al. (2006) study.
We observed that the TT genotype in C3435T was less
common in male cases than in controls and this points to a
different direction when compared to the reports of Fujii et al.
(2012) and Qian et al. (2006). These nonconcordant results may
be explained by two lines of evidence. First, both studies
evaluated MDD risk in Asian subjects. The genetic variability
of the ABCB1 polymorphisms is known to diverge among
ethnic groups (Ameyaw et al., 2001; Sipeky et al., 2011), as
shown in Table 4. Second, no stratification on gender was
present in these studies. As proposed by Becker et al., (2009)
gender stratification is essential when evaluating the effect of
these ABCB1 polymorphisms, since they are found to be as-
sociated with the cholesterol-lowering effect of simvastatin
only in males. Additionally, it has been proposed by several
authors that different susceptibility of depression is under the
major influence of gender (Unschuld et al., 2010).
Haplotype analysis in ABCB1 polymorphisms, rather than
a single SNP, may provide an advantage in the diagnosis of
complex diseases, such as MDD. In fact, there are reports of
significant correlations found using ABCB1 1236T-2677T-
3435T haplotype analysis and lack of association when each
SNP was analyzed separately (Potocnik et al., 2004; Kimchi-
Sarfaty et al., 2007a). We observed that the ABCB1 1236T-
2677T-3435T haplotype presents a protective effect since the
male carriers of this profile have a lower risk of developing
MDD (OR = 0.313, 95% CI: [0.118–0.832], p= 0.016). Clinical
studies have shown that the 1236T-2677T-3435T haplotype is
also associated with reduced P-GP activity (Salama et al.,
2006). Indeed, recombinant cells expressing ABCB1 1236T-
2677T-3435T variants displayed only 0–22.7% transporter
activity, which suggests that this haplotype significantly re-
duces P-GP functionality in vitro, losing about 80%-100% of its
efflux capability (Salama et al., 2006). Although some authors
defend that the lack of P-GP function could lead to the accu-
mulation of deleterious substances, such as neurotoxins, and
represent a risk of MDD development (Fujii et al., 2012), we
hypothesized that male carriers of the 1236T-2677T-3435T
haplotype may have a less active transporter and this might
be protective for the risk of MDD. P-GP is known to in vivo
regulate brain access of endogenous steroid hormones (Uhr
et al., 2002; Binder et al., 2009). In normal subjects, the HPA
axis is regulated by a negative feedback control, whereby
glucocorticoids secreted from the adrenal gland suppress the
hypothalamus to secret the corticotrophin releasing hormone
(CRH) and arginine–vasopressin, which per se limits the re-
lease of corticotrophin (ACTH) from the anterior pituitary,
and thus promotes less glucocorticoid release from adrenal
glands (O’Brien et al., 2012). In depressed patients, this neg-
ative feedback control is impaired and patients display HPA
axis hyperactivity, evident by an increased cortisol concen-
tration in serum, urine, and the cerebrospinal fluid (Holsboer,
2000; Pariante and Miller, 2001).
Our hypothesis is that the putative lower P-GP function,
found in carriers of the 1236T/2677T/3435T haplotype, may
restrain HPA system activation after stressful events, and
induce a chronically increased negative feedback at the hy-
pothalamic level due to an enhanced penetration of gluco-
corticoid hormones into the central nervous system, and
promote a less active HPA response under stress conditions.
Interestingly, in vivo studies using abcb1ab ( -/ - ) mice mu-
tants prove that the absence of P-GP leads to an increased
penetration of corticosteroid hormones in the central nervous
system, which in turn, enhanced central negative feedback
inhibition of stress hormone secretion, with lower plasma
ACTH levels in both at basal and under stress conditions
(Muller et al., 2003). Moreover, antidepressants have also in-
hibited P-GP in vitro, and decreased the HPA axis activity
in vivo, leading to the hypothesis that antidepressants inhibit
P-GP at the BBB and increase glucocorticoid access to the
brain (Yau et al., 2007).
The gender-specific trait of our results can be explained by
the differential expression of P-GP in male and female (Suzuki
et al., 2006; Bebawy and Chetty, 2009). Sex hormones can
regulate the expression of P-GP in systemic organs, contrib-
uting to the differences observed in metabolic disposition
(Compton et al., 2006). Interestingly, the male androgens
suppress P-GP expression and function, contrary to what is
reported for the female sex hormones, but the precise mech-
anism for testosterone repression of P-GP expression remains
undefined (Suzuki et al., 2006). Moreover, a distinct HPA axis
activation among male and female might explain our results.
Binder et al., (2009) observed a normalization of HPA axis
reactivity, illustrated by the dexamethasone-resistant test,
only among male patients with remission of depressive
symptoms. Another report showed that knockdown of glu-
cocorticoid receptors in the medial prefrontal cortex, hippo-
campus, and basolateral amygdala induces depression-like
behaviors in male mice, but not in females (Solomon et al.,
2012). This author suggests that this mechanism for devel-
opment of mood disorders holds only in males and provable
symptoms of depression are mediated by an alternative brain
circuitry and/or different molecular substrates in comparison
with female gender individuals (Solomon et al., 2012). Ad-
ditionally, several reports in the literature regarding depression
and antidepressant responses, point out for differences among
male and female patients (Schaich et al., 2009; Kurita et al.,
2012). The absence of a significant association in women found
in our study does not exclude the fact that genetic variation in
ABCB1 does affect the risk of MDD development in women,
but the effect is most likely weaker in women than in males.
The main limitation of our study is the relatively low
number of subjects genotyped. Major concerns of small
sample studies are false-positive results and over-estimation
of magnitude association. To exclude false-positive results,
FDR correction was included for multiple comparisons, and
our results remain statistically significant for the TTT haplo-
type. In this study, high magnitude associations (OR ‡ 1.75
and £ 0.55) are detected with an 80% statistical power, like the
one we found for the male TTT haplotype. However, it is
possible that small effects are not detected with our sample.
Control selection bias was excluded by comparing genotypic
INFLUENCE OF ABCB1 POLYMORPHISMS IN MDD RISK 17
frequencies of our controls and other southern Caucasian
samples, including Portuguese. Although our study was the
first to analyze the influence of ABCB1 C1236T, C3435T and
G2677TA polymorphisms in a Caucasian subset of MDD pa-
tients, independent association studies with larger sample
sizes are needed to confirm the influence of these SNPs in
MDD development risk.
In conclusion, this article adds clinical evidence that genetic
variability of theABCB1 is associated with MDD in males, and
that this may influence the HPA system activity, through a
less active P-GP. The observed sex differences in ABCB1
polymorphisms and risk of MDD may explain a gender di-
morphic sensitivity of the HPA axis and hypothetically reflect
a gender-specific pathophysiology of depression.
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